KR100608415B1 - 폴리알킬렌 글리콜산 첨가제 - Google Patents

폴리알킬렌 글리콜산 첨가제 Download PDF

Info

Publication number
KR100608415B1
KR100608415B1 KR1020057001328A KR20057001328A KR100608415B1 KR 100608415 B1 KR100608415 B1 KR 100608415B1 KR 1020057001328 A KR1020057001328 A KR 1020057001328A KR 20057001328 A KR20057001328 A KR 20057001328A KR 100608415 B1 KR100608415 B1 KR 100608415B1
Authority
KR
South Korea
Prior art keywords
formula
pag
ester
compound
molecular weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020057001328A
Other languages
English (en)
Korean (ko)
Other versions
KR20050025663A (ko
Inventor
바일론파스칼세바스티안
원치엽
Original Assignee
에프. 호프만-라 로슈 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에프. 호프만-라 로슈 아게 filed Critical 에프. 호프만-라 로슈 아게
Publication of KR20050025663A publication Critical patent/KR20050025663A/ko
Application granted granted Critical
Publication of KR100608415B1 publication Critical patent/KR100608415B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32Polymers modified by chemical after-treatment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32Polymers modified by chemical after-treatment
    • C08G65/329Polymers modified by chemical after-treatment with organic compounds
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32Polymers modified by chemical after-treatment
    • C08G65/329Polymers modified by chemical after-treatment with organic compounds
    • C08G65/331Polymers modified by chemical after-treatment with organic compounds containing oxygen
    • C08G65/332Polymers modified by chemical after-treatment with organic compounds containing oxygen containing carboxyl groups, or halides, or esters thereof
    • C08G65/3322Polymers modified by chemical after-treatment with organic compounds containing oxygen containing carboxyl groups, or halides, or esters thereof acyclic
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32Polymers modified by chemical after-treatment
    • C08G65/329Polymers modified by chemical after-treatment with organic compounds
    • C08G65/337Polymers modified by chemical after-treatment with organic compounds containing other elements
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08LCOMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2203/00Applications
    • C08L2203/02Applications for biomedical use

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Polyethers (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020057001328A 2002-07-24 2003-07-16 폴리알킬렌 글리콜산 첨가제 Expired - Fee Related KR100608415B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39813702P 2002-07-24 2002-07-24
US60/398,137 2002-07-24

Publications (2)

Publication Number Publication Date
KR20050025663A KR20050025663A (ko) 2005-03-14
KR100608415B1 true KR100608415B1 (ko) 2006-08-02

Family

ID=31495718

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020057001328A Expired - Fee Related KR100608415B1 (ko) 2002-07-24 2003-07-16 폴리알킬렌 글리콜산 첨가제

Country Status (13)

Country Link
US (2) US7193031B2 (enExample)
EP (1) EP1526872A1 (enExample)
JP (2) JP4451308B2 (enExample)
KR (1) KR100608415B1 (enExample)
CN (1) CN100337689C (enExample)
AR (1) AR040654A1 (enExample)
AU (1) AU2003258518B2 (enExample)
BR (1) BR0313212A (enExample)
CA (1) CA2492775C (enExample)
MX (1) MXPA05000796A (enExample)
PL (1) PL375265A1 (enExample)
RU (1) RU2318004C2 (enExample)
WO (1) WO2004012773A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
ATE477020T1 (de) 2002-06-07 2010-08-15 Dyax Corp Prevention und verringerung von ischemia
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
JP4451308B2 (ja) * 2002-07-24 2010-04-14 エフ.ホフマン−ラ ロシュ アーゲー ポリアルキレングリコール酸添加剤
WO2005021557A2 (en) * 2003-08-29 2005-03-10 Dyax Corp. Poly-pegylated protease inhibitors
CA2537113A1 (en) * 2003-08-29 2005-03-10 Dyax Corp. Modified protease inhibitors
KR101276422B1 (ko) 2004-03-15 2013-06-19 넥타르 테라퓨틱스 Hiv 유입 억제제의 중합체-기재 조성물 및 콘쥬게이트
CA2567630A1 (en) * 2004-05-17 2005-11-24 Mcmaster University Biological molecule-reactive hydrophilic silicone surface
ATE491475T1 (de) * 2004-07-16 2011-01-15 Nektar Therapeutics Konjugate enthaltend gm-csf und ein polymer
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
ATE425204T1 (de) * 2005-08-26 2009-03-15 Novo Nordisk As Verfahren zur modifizierung eines makromolekularen systems
US8133707B2 (en) * 2006-01-17 2012-03-13 Enzon Pharmaceuticals, Inc. Methods of preparing activated polymers having alpha nitrogen groups
AR067536A1 (es) 2007-07-17 2009-10-14 Hoffmann La Roche Metodo para obtener una eritropoyetina mono-pegilada en una forma sustancialmente homogenea
CL2008002053A1 (es) * 2007-07-17 2009-05-22 Hoffmann La Roche Metodo para la purificacion de una eritropoyetina monopeguilada (epompeg) que consiste en proporcionar una solucion que contiene eritropoyetina mono, poli y no peguilada y hacerla pasar por dos pasos de cromatografia de intercambio cationico y metodo para producir epo mpeg que incluye metodo de purificacion.
US20090075887A1 (en) * 2007-08-21 2009-03-19 Genzyme Corporation Treatment with Kallikrein Inhibitors
KR101671537B1 (ko) 2008-08-11 2016-11-01 넥타르 테라퓨틱스 다분지형 중합체 알카노에이트 컨쥬게이트
EP2385843A4 (en) 2009-01-06 2013-02-27 Dyax Corp TREATMENT OF MUZOSITIS WITH CALLICINE INHIBITORS
EP4011917A1 (en) 2010-01-06 2022-06-15 Takeda Pharmaceutical Company Limited Plasma kallikrein binding proteins
US10040761B2 (en) * 2010-06-25 2018-08-07 Nof Corporation Branched hetero polyethylene glycol and intermediate
WO2012088422A1 (en) 2010-12-22 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
WO2012088445A1 (en) 2010-12-22 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
AU2012204202A1 (en) 2011-01-06 2013-07-11 Dyax Corp. Plasma kallikrein binding proteins
MX358784B (es) 2012-04-03 2018-09-04 Sangart Inc Compuestos de nitroxilo activados con succinimida y metodos para el uso de los mismos para nitroxilacion de proteinas.
CN102816227A (zh) * 2012-08-30 2012-12-12 深圳赛保尔生物药业有限公司 回收促红细胞生成素的方法
EP2968597B1 (en) 2013-03-15 2021-08-18 Schindler, William Polyalkylene oxide valerate hemoglobin conjugates
KR20230109785A (ko) 2014-03-27 2023-07-20 다케다 파머수티컬 컴패니 리미티드 당뇨병성 황반 부종의 치료를 위한 조성물 및 방법
IL311156A (en) 2015-12-11 2024-04-01 Takeda Pharmaceuticals Co Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
CN113631631B (zh) * 2019-03-29 2023-04-18 日油株式会社 含末端羧基的聚乙二醇的制备方法以及活化聚乙二醇的制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5849450B2 (ja) * 1975-07-09 1983-11-04 株式会社日立製作所 スイリヨクシキカプセルユソウソウチノ ボウシクホウ
EP0206448B1 (en) * 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
JP2531661B2 (ja) 1987-02-25 1996-09-04 味の素株式会社 酸素運搬剤
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5382657A (en) 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
KR960705579A (ko) * 1993-11-10 1996-11-08 에릭에스. 딕커 개선된 인터페론 중합체 결합체(Improved interferon polymer conjugates)
US5672662A (en) * 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
PT957929E (pt) * 1996-10-25 2006-06-30 Gilead Sciences Inc Complexos de ligandos de acido nucleico do factor de crescimento endotelial vascular
CN1376164A (zh) 1999-01-29 2002-10-23 霍夫曼-拉罗奇有限公司 Gcsf缀合物
PE20001548A1 (es) 1999-03-02 2001-01-16 Schering Corp Uso de interferon alfa pegilado para el tratamiento de vih-1
CZ299516B6 (cs) 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
CN1284603C (zh) 1999-10-08 2006-11-15 内科塔治疗亚拉巴马公司 杂双官能聚乙二醇衍生物和它们的制备方法
KR100653153B1 (ko) * 1999-12-22 2006-12-01 넥타르 테라퓨틱스 에이엘, 코포레이션 수용성 중합체의 입체장애 유도체
US20020065397A1 (en) 2000-10-12 2002-05-30 Joseph Roberts Protecting therapeutic compositions from host-mediated inactivation
EP1345628B1 (en) * 2000-12-20 2011-04-13 F. Hoffmann-La Roche AG Conjugates of erythropoietin (epo) with polyethylene glycol (peg)
JP4451308B2 (ja) * 2002-07-24 2010-04-14 エフ.ホフマン−ラ ロシュ アーゲー ポリアルキレングリコール酸添加剤

Also Published As

Publication number Publication date
PL375265A1 (en) 2005-11-28
CN100337689C (zh) 2007-09-19
US20060167218A1 (en) 2006-07-27
AU2003258518A1 (en) 2004-02-23
JP5112203B2 (ja) 2013-01-09
RU2005105580A (ru) 2006-01-20
US7504477B2 (en) 2009-03-17
AU2003258518B2 (en) 2007-01-18
CN1671422A (zh) 2005-09-21
JP2006502250A (ja) 2006-01-19
US20040106747A1 (en) 2004-06-03
JP4451308B2 (ja) 2010-04-14
BR0313212A (pt) 2005-06-28
AR040654A1 (es) 2005-04-13
RU2318004C2 (ru) 2008-02-27
KR20050025663A (ko) 2005-03-14
US7193031B2 (en) 2007-03-20
CA2492775A1 (en) 2004-02-12
MXPA05000796A (es) 2005-04-19
WO2004012773A1 (en) 2004-02-12
CA2492775C (en) 2011-06-21
EP1526872A1 (en) 2005-05-04
JP2009062516A (ja) 2009-03-26

Similar Documents

Publication Publication Date Title
KR100608415B1 (ko) 폴리알킬렌 글리콜산 첨가제
JP4344110B2 (ja) ヘテロ二官能性ポリエチレングリコール誘導体およびその調製方法
US5990237A (en) Poly(ethylene glycol) aldehyde hydrates and related polymers and applications in modifying amines
CN1039015C (zh) 聚乙二醇-干扰素结合物
US20020072573A1 (en) Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
US8940801B2 (en) Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
US20040034188A1 (en) Novel monofunctional polyethylene glycol aldehydes
EP1507755A2 (en) Novel monofunctional polyethylene glycol aldehydes
US20040122164A1 (en) Novel monofunctional polyethylene glycol aldehydes
US20030153694A1 (en) Novel monofunctional polyethylene glycol aldehydes
US20040147687A1 (en) Novel monofunctional polyethylene glycol aldehydes
KR100480432B1 (ko) G-csf와 폴리에틸렌글리콜 유도체의 배합체
KR100480423B1 (ko) 에리트로포이에틴과 폴리에틸렌글리콜 유도체의 배합체
KR100761652B1 (ko) 단백질 또는 펩타이드에 결합되는 다가지의 고분자유도체와 접합체
JP2018115338A (ja) ヘテロ二官能性ポリエチレングリコール誘導体およびその調製方法
JP2017197770A (ja) ヘテロ二官能性ポリエチレングリコール誘導体およびその調製方法
WO2007078820A2 (en) Methylmaleimidyl polymer derivatives
JP2016029182A (ja) ヘテロ二官能性ポリエチレングリコール誘導体およびその調製方法

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

FPAY Annual fee payment

Payment date: 20120628

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

FPAY Annual fee payment

Payment date: 20130628

Year of fee payment: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20140727

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20140727

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000